Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at JPMorgan Chase & Co. from $39.00 to $40.00. They now have an "overweight" rating on the stock.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at Evercore ISI from $30.00 to $35.00. They now have an "outperform" rating on the stock.
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
Here's What Could Help Kiniksa Pharmaceuticals (KNSA) Maintain Its Recent Price Strength [Yahoo! Finance]